Latest Sunitinib Stories
By Ashley Andyshak, The Frederick News-Post, Md. Aug. 2--Frederick Memorial Hospital Regional Cancer Therapy Center has received a $30,000 grant to improve its clinical research programs.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that the State Food and Drug Administration of China has approved Nexavar tablets for the treatment of patients with unresectable or metastatic hepatocellular carcinoma, or liver cancer.
Introgen Therapeutics has reported additional efficacy data from the company's recent regulatory filings seeking approval of Advexin in the US and Europe.
BELLEVUE, WA, June 17 /PRNewswire-FirstCall/ -- Oncothyreon Inc. (TSX:ONY) today announced enrollment of the first patient in a Phase 1 trial of PX-866 in patients with advanced solid tumors.
By Barry Nelson A PROFESSOR who successfully "declared war" on cancer in France has urged the British Government to give more priority to the disease.
COLLEGEVILLE, Pa., May 31 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , today announced results of a three-arm phase 3 clinical trial that show patients with relapsed and/or refractory mantle cell lymphoma (MCL), a form of non-Hodgkin's lymphoma, treated with the mTOR (mammalian target of rapamycin) inhibitor TORISEL(R) (temsirolimus) experienced a statistically significant improvement in median progression-free survival (PFS), compared with single-agent therapy...
Please read in fourth paragraph ... "24 weeks from 12 weeks" ... instead of ...
By Toni Clarke ATLANTA (Reuters) - A kidney cancer drug made by Bayer AG and Onyx Pharmaceuticals Inc. showed promise in a small lung cancer trial, according to data released on Sunday, further fueling competition with a drug from Pfizer Inc.
By Toni Clarke ATLANTA (Reuters) - For the first time in decades there are new treatments available for kidney cancer, and as more data emerges about their efficacy, the competition looks set to heat up.
By Toni Clarke ATLANTA (Reuters) - Wyeth said on Sunday that interim results of a late-stage trial of its experimental kidney cancer drug significantly increased survival in patients compared to standard therapy.
- A hairdresser.